According to the research by Mao et al., 34.0% of AML patients had MMR gene mutation or MLH1 promoter methylation, and the incidence of MMR deficiency in refractory or recurrent AML patients was significantly higher than that in newly diagnosed patients40. Here, MLH1 is linked to mismatch repair cancer syndrome 1.